Apixaban-PK Trial for Portal Hypertension, Cirrhosis

ClinicalTrials.gov published registration details for a new observational pharmacokinetic study (NCT07521332) investigating apixaban in patients with portal hypertension and compensated or decompensated cirrhosis. The trial will collect PK blood samples and follow clinical outcomes without administering investigational drug.

Affected parties including trial sponsors, clinical investigators, and institutional review boards should ensure compliance with ClinicalTrials.gov registration and results posting requirements under the FDA Amendments Act. Healthcare organizations conducting clinical research should verify their active trials are properly registered and updated.